ReviewNatural products and bioprospecting2026
Advanced delivery of natural bioactive compounds for atopic dermatitis: a review of polymeric conjugates and nanocarriers.
Review in Natural products and bioprospecting, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Herbal Extracts and Plant-Derived Bioactives in Atopic Dermatitis: Evidence, Mechanisms, Pediatric Safety, and Translational Priorities.Food science & nutrition · 2026Review
- The Therapeutic Potential of Polyphenols in Modulating Barrier Lipids, Microbiome Interactions, and Inflammatory Pathways in Atopic Dermatitis.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a persistent, relapsing skin inflammatory disorder characterised by epidermal barrier dysfunction, immune system anomalies, and microbial dysbiosis. Current therapies encompass calcineurin inhibitors, topical corticosteroids, and synthetic drugs such as JAK inhibitors and biologics, which, despite their efficacy, have safety issues and constraints on prolonged use. Recently, natural bioactive compounds namely flavonoids, polyphenols, and terpenoids have garnered interest for their anti-inflammatory, antioxidant, and skin-barrier-repairing characteristics. Recent studies emphasise the incorporation of these bioactive compounds into hydrophilic/hydrophobic polymeric conjugates and nanocarrier systems to promote skin distribution, increase efficacy, and minimise systemic adverse effects. This study encapsulates traditional and innovative medicines, highlights the promise of polymer-conjugated herbal formulations, and examines recent developments in nanotechnology and delivery technologies for AD management. The increasing interest in bioactive ingredient formulations and polymeric nanocarriers indicates a favourable shift towards safer, more effective, and patient-compliant treatment methodologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.